GE HealthCare Reports the US FDA’s Approval of Flyrcado (Flurpiridaz F 18) PET Radiotracer for Improved CAD Diagnosis
Shots:
-
The US FDA has approved Flyrcado injection as a PET MPI agent to diagnose CAD, with its launch planned in early 2025
-
The effectiveness of Flyrcado was assessed under the P-III (AURORA) study in comparison with both invasive coronary angiography as a standard and SPECT MPI to identify CAD
-
In addition, GE HealthCare secured exclusive global commercialization rights of the flurpiridaz F 18 from Lantheus in 2017, funding its development until approval. Lantheus will partner on commercialization through a joint steering committee & is entitled to get royalties based on sales milestones
Ref: GE Healthcare | Image: GE Healthcare
Related News:- GE HealthCare Reports the P-I Study Data of its Macrocyclic Manganese-Based MRI Contrast Agent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
